about
Cellular and molecular mechanisms underlying age-related skeletal muscle wasting and weaknessDeletion of skeletal muscle SOCS3 prevents insulin resistance in obesityEmerging drugs for sarcopenia: age-related muscle wastingCytoskeletal tropomyosin Tm5NM1 is required for normal excitation-contraction coupling in skeletal muscleThe orphan nuclear receptor, NOR-1, a target of beta-adrenergic signaling, regulates gene expression that controls oxidative metabolism in skeletal muscleAgeing prolongs inflammatory marker expression in regenerating rat skeletal muscles after injuryExpression of the AMP-activated protein kinase beta1 and beta2 subunits in skeletal muscleHsp72 preserves muscle function and slows progression of severe muscular dystrophyExpression profiling of skeletal muscle following acute and chronic beta2-adrenergic stimulation: implications for hypertrophy, metabolism and circadian rhythm.Making fast-twitch dystrophic muscles bigger protects them from contraction injury and attenuates the dystrophic pathology.G-CSF does not influence C2C12 myogenesis despite receptor expression in healthy and dystrophic skeletal muscle.Antibody-directed myostatin inhibition improves diaphragm pathology in young but not adult dystrophic mdx mice.Functional β-adrenoceptors are important for early muscle regeneration in mice through effects on myoblast proliferation and differentiationWhole body deletion of AMP-activated protein kinase {beta}2 reduces muscle AMPK activity and exercise capacity.The orphan nuclear receptor, NOR-1, is a target of beta-adrenergic signaling in skeletal muscle.Arginine protects muscle cells from wasting in vitro in an mTORC1-dependent and NO-independent manner.Separation of fast from slow anabolism by site-specific PEGylation of insulin-like growth factor I (IGF-I).FHL1 reduces dystrophy in transgenic mice overexpressing FSHD muscular dystrophy region gene 1 (FRG1).Dysfunctional muscle and liver glycogen metabolism in mdx dystrophic miceSystemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses.Modulation of insulin-like growth factor (IGF)-I and IGF-binding protein interactions enhances skeletal muscle regeneration and ameliorates the dystrophic pathology in mdx mice.Importance of functional and metabolic impairments in the characterization of the C-26 murine model of cancer cachexia.Parvalbumin gene transfer impairs skeletal muscle contractility in old miceDuchenne muscular dystrophy: focus on pharmaceutical and nutritional interventions.Therapeutic approaches for muscle wasting disorders.Force deficits and breakage rates after single lengthening contractions of single fast fibers from unconditioned and conditioned muscles of young and old ratsTowards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophyRole of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease.Anabolic agents for improving muscle regeneration and function after injury.The potential and the pitfalls of beta-adrenoceptor agonists for the management of skeletal muscle wasting.Update on emerging drugs for sarcopenia - age-related muscle wasting.Tranilast administration reduces fibrosis and improves fatigue resistance in muscles of mdx dystrophic mice.The role of beta-adrenoceptor signaling in skeletal muscle: therapeutic implications for muscle wasting disorders.Novel role for ß-adrenergic signalling in skeletal muscle growth, development and regeneration.Update on emerging drugs for cancer cachexia.Emerging drugs for treating skeletal muscle injury and promoting muscle repair.Leucine as a treatment for muscle wasting: a critical review.Examination of 'lipotoxicity' in skeletal muscle of high-fat fed and ob/ob mice.Elevated expression of activins promotes muscle wasting and cachexia.Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia.
P50
Q28270123-AA28B41C-E066-4AB1-8F84-EAFEB2311675Q28274712-5AB7CB25-A80D-4533-B756-39E390F890AEQ28295716-7CF56456-0875-4C52-9483-CC71112C79E5Q28300662-51CCF85B-5403-4DA3-8383-592EEE375B9FQ28508840-5CADC34C-CAFE-4092-98B1-7B0CF61B5CA8Q28565133-7DB7324C-3561-45AE-AD24-FAFAD1EFF482Q28581653-7168BF65-1586-4DAE-A8CC-94B12B16A21BQ28591442-35FFB8C8-7300-4EB6-98C3-B1BFDED4B1A1Q30157109-49802D4B-2BA7-4F3F-A843-93280816B99FQ33556205-F2C315CA-DFB6-4305-B166-1541F8083511Q33579922-CEB77532-A15D-48A8-98CA-38F115ED29A6Q33816426-C19530DD-BEB5-4C5E-81BF-CBFA712F0A43Q33855954-D020F665-1E61-4F9E-BC5F-D17EC3F41C11Q34333517-4ECD6B85-970A-42E5-9970-C07B010B1FE6Q34556274-D0344751-FA62-47DA-AE0B-A31FE6461CFAQ34663782-9B477DB9-C189-4397-B2BB-E5AB57DDB734Q35010965-4B98A731-7997-44A6-B476-91168AD05696Q35103393-DCDAA919-D1B0-435C-9ED7-242CBFBFE905Q35120208-FA60F29F-D261-45E7-812A-3C9E8ACD542FQ35545362-6C8840F6-D8C6-4CEA-A4C8-610FD6345EDFQ36007403-FFDBF530-4BD0-440B-83D3-5DC87A040119Q36051080-EE25BEED-A95A-4AA7-A05A-F75B1B3B66AEQ36147528-931E8B82-36A1-4308-BE57-7B8988E9227AQ36669820-CA2177F2-C326-4EA5-A233-57D8A646AC54Q36720401-E4C4575E-EB44-4071-A088-8F7F0536DBB8Q36805348-2C13AD6F-FC87-4C9F-86CA-A83D7A55F3D7Q36841572-BCD0762F-55D2-4C8B-B464-EB6CA2300BBAQ37129351-AC9A1A01-17F3-4DCB-859F-DAED3BBB9518Q37171075-6155DA0B-7622-46B9-A1BE-4CF88338648CQ37286415-3D7F6CC2-9F62-46CA-A56D-875DD732FDBFQ37338308-D45E9B07-AAA6-468A-ADD3-CBA32AC41C5DQ37539643-3DE1D3D7-C7E4-45C5-95EF-587BFB2E9E95Q37594502-B150DBF3-50C9-4497-9435-CF19929529A7Q37605915-EE12A943-DADE-4D37-BBD3-329EA3ED713EQ37622253-4AEDD8D6-C59F-4C57-B66D-85D52D658EE2Q37842502-32386F3A-1C39-4FB3-AC39-75B6C97A8EEFQ38274694-C5A53188-7AC5-4CED-83E1-26C80A5F39C7Q38356734-5E1C539F-1000-4E1E-BFA4-31C94FE76AACQ39038278-4C2F095D-B9A0-4B6F-B097-ED7F240F7068Q39128938-E4F71063-BD0A-4BF8-9DC8-0C56E3F7E676
P50
subject
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Gordon S Lynch
@nl
Gordon S Lynch
@sl
Gordon S. Lynch
@en
Gordon S. Lynch
@es
type
label
Gordon S Lynch
@nl
Gordon S Lynch
@sl
Gordon S. Lynch
@en
Gordon S. Lynch
@es
prefLabel
Gordon S Lynch
@nl
Gordon S Lynch
@sl
Gordon S. Lynch
@en
Gordon S. Lynch
@es
P1006
P214
P1006
P1053
G-9553-2015
P106
P1153
7201401199
P21
P214
P31
P3829
P496
0000-0001-9220-9810
P734
P735
P7859
lccn-nb2011000522